-
公开(公告)号：US11850535B2
公开(公告)日：2023-12-26
申请号：US18067803
申请日：2022-12-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Dingjiang Liu , Lin Luo , Long Xu
CPC classification number: B01D15/30 , A61K39/39591 , B01D15/327 , C07K16/00 , C07K16/06 , C07K16/065 , C07K16/10 , G01N30/02 , G01N33/6854 , G01N2030/027
Abstract: The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when nm alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
-
公开(公告)号：US11850407B2
公开(公告)日：2023-12-26
申请号：US17930502
申请日：2022-09-08
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Bryan Grygus , Richard Jeff Gildersleeve , Shaina Varghese
CPC classification number: A61M5/3204 , B29C45/14819 , B29C45/2602 , F16B2/245 , A61M2207/00 , B29L2031/7544
Abstract: A needle guard grip device may include a body extending from a first end to a second end along a central longitudinal axis of the body. The body may include a plurality of ribs extending perpendicularly to the central longitudinal axis. The plurality of ribs may include a first set of longitudinally spaced ribs disposed on a first side of the central longitudinal axis, and a second set of longitudinally spaced ribs disposed on a second side of the central longitudinal axis that is opposite of the first side. Moving along the central longitudinal axis, ribs of the first set of longitudinally spaced ribs may alternate with ribs of the second set of longitudinally spaced ribs.
-
公开(公告)号：US20230406959A1
公开(公告)日：2023-12-21
申请号：US18308769
申请日：2023-04-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Scott M. WALSH , Daniel B. DIX
CPC classification number: C07K16/40 , A61K39/39591 , A61K39/3955 , A61K47/22 , A61K47/26 , A61M5/31513 , A61M5/3202 , C07K2317/565 , C07K2317/94
Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
-
公开(公告)号：US11845930B2
公开(公告)日：2023-12-19
申请号：US16821607
申请日：2020-03-17
Applicant: Regeneron Pharmaceuticals Inc.
CPC classification number: C12N15/1079 , C12Q1/6874 , G01N33/5008 , G16B20/00 , G16B25/00 , G16B30/00
Abstract: Methods and systems for CRISPR positive selection are described. CRISPR positive selection uses DNA sequencing to identify genes that their perturbation by CRISPR guide RNAs is correlated to the phenotype. In some aspects, disclosed are genome-wide CRISPR/Cas9 screening methods to identify genetic modifiers. Also disclosed are the apparatuses used for performing the methods.
-
95.发明公开公开(公告)号：US20230399410A1
公开(公告)日：2023-12-14
申请号：US18130980
申请日：2023-04-05
Applicant: Sanofi Biotechnology , Regeneron Pharmaceuticals, Inc.
Inventor： Jennifer SLOANE LAZAR , Yong LIN , Wanling WONG , Ying LIU , Frédéric MARRACHE , Kerri FORD , Stefano FIORE , Lita ARAUJO , Danielle ISAMAN , Jeffrey CURTIS , Chad NIVENS , Bola AKINLADE , Angeliki GIANNELOU
IPC: C07K16/28 , A61P21/00 , A61K31/573 , A61K39/395 , A61P29/00
CPC classification number: C07K16/2866 , A61P21/00 , A61K31/573 , A61K39/3955 , A61P29/00 , A61K2039/505
Abstract: The present disclosure relates to the use of an anti-IL6 receptor antibody, or an antigen-binding fragment thereof, for treating polymyalgia rheumatica (PMR).
-
Patent Agency Ranking
公开(公告)号：US20230391844A1
公开(公告)日：2023-12-07
申请号：US18328327
申请日：2023-06-02
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jiaxi WU , Supriya PATEL , Tong ZHANG , Nicolin BLOCH , Eric SMITH , Chia-Yang LIN , Vidur GARG , Erica ULLMAN
IPC: C07K14/555 , A61P35/00 , C07K14/715
CPC classification number: C07K14/555 , A61P35/00 , C07K14/7155 , A61K38/00
Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2Rα moiety and a protease-cleavable linker, configured such that the IL2Rα moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
-
公开(公告)号：US20230382969A1
公开(公告)日：2023-11-30
申请号：US18324380
申请日：2023-05-26
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Supriya PATEL , Tong ZHANG , Jiaxi WU , Aaron CHANG , Eric SMITH , Chia-Yang LIN , Samuel DAVIS
Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2Rα moiety and a protease-cleavable linker, configured such that the IL2Rα moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
-
公开(公告)号：US20230374160A1
公开(公告)日：2023-11-23
申请号：US18247226
申请日：2021-10-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur Hermann , Erica Ullman , Min Zhu , Masood Khaksar Toroghi
CPC classification number: C07K16/468 , C07K16/2818 , A61P35/00 , C07K2317/31 , C07K2317/565
Abstract: This disclosure provides methods for treating cancer and for ameliorating cytokine release syndrome in a subject with a tumor. The methods include administering to a subject in need thereof a bispecific anti-CD20/anti-CD3 antibody before administering to the subject an anti-PD-1 antibody. The disclosed methods represent effective therapies for cancer, e.g, B-cell malignancies, with mitigation of the potential life-threatening effects of cytokine release syndrome (CRS).
-
公开(公告)号：US20230374108A1
公开(公告)日：2023-11-23
申请号：US18344786
申请日：2023-06-29
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Eric FURFINE , Daniel DIX , Kenneth GRAHAM , Kelly FRYE
IPC: C07K14/71 , A61K9/00 , A61K9/19 , A61K38/17 , C07K14/47 , A61M5/178 , A61K47/26 , A61K47/02 , A61K47/10
CPC classification number: C07K14/71 , A61K9/0048 , A61K9/19 , A61K38/1793 , C07K14/4705 , A61M5/178 , C07K14/47 , A61K9/0019 , A61K38/179 , A61K47/26 , A61K47/02 , A61K47/10 , C07K2319/30 , C07K2319/00
Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
-
公开(公告)号：US11820826B2
公开(公告)日：2023-11-21
申请号：US17692084
申请日：2022-03-10
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Michael E. Dunn , Jia Su , Jason Mastaitis , Jesper Gromada , Lori C. Morton
CPC classification number: C07K16/2869 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61P3/04 , A61P9/02 , A61P9/12 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.
-
-
-
-
-
-
-
-
-
Search Results
2865
records
(took 0.033 seconds)
